NCT01406288

Brief Summary

The Hemolytic Uremic Syndrome (HUS) in its typical form occurs after a food born infection with a shiga-toxin secreting bacteria, usually Escherichia coli of the O157H7 serotype. An outbreak of bloody diarrhea followed by HUS begun after a collective meal with 120 persons on June 8th, 2011 in Bègles, a city of Bordeaux urban area (CUB). At least 9 patients, 8 adults and 1 child have been involved in this HUS outbreak, E. coli of the O104:H4 serotype being demonstrated in most patients. This outbreak is remarkable by its preponderance in adults and women, its aggressiveness with multiorgan involvement , i.e. the kidneys, brain, liver, pancreas, and skin. Pathophysiology, prognosis, and treatment of typical HUS are poorly defined, particularly in adults who are usually not involved in typical E. coli O157H7 HUS. The aim of the present study is to gain knowledge on these different aspects of the HUS, including response to therapy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2011

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2011

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

July 28, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 1, 2011

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

November 20, 2012

Status Verified

November 1, 2012

Enrollment Period

8 months

First QC Date

July 28, 2011

Last Update Submit

November 19, 2012

Conditions

Keywords

hemolytic-uremic syndromeshiga-toxin-producing E. Coli

Outcome Measures

Primary Outcomes (1)

  • Improve scientific knowledge on epidemic HUS in the context of an outbreak of E. coli O104:H4 HUS in the town of Bègles, urban area of Bordeaux, France

    This is an observational propspective study in which all data will be collected on all pertinent aspects of disease, including therapeutic regimens.

    during patient hospitalization

Secondary Outcomes (1)

  • evaluate efficiency of therapeutic and diagnostic strategies

    during patient hospitalization

Study Arms (1)

HUS epidemy in Bordeaux, E. coli of the O104H4 serotype

Other: HUS standard coverage care (including in ICU)

Interventions

HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption

HUS epidemy in Bordeaux, E. coli of the O104H4 serotype

Eligibility Criteria

Age2 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

dinner guest to a collective meal on June 8th, 2011 in Bègles, a city of Bordeaux urban area (CUB).

You may qualify if:

  • All patients with HUS concomitant to the outbreak linked to E. coli O104:H4

You may not qualify if:

  • Patient not willing to participate or to sign informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service de Néphrologie, transplantation dialyse - Hôpital Pellegrin

Bordeaux, 33076, France

Location

MeSH Terms

Conditions

Hemolytic-Uremic SyndromeEscherichia coli Infections

Interventions

Intensive Care Units

Condition Hierarchy (Ancestors)

UremiaKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesAnemia, HemolyticAnemiaHematologic DiseasesHemic and Lymphatic DiseasesThrombotic MicroangiopathiesThrombocytopeniaBlood Platelet DisordersCytopeniaEnterobacteriaceae InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections

Intervention Hierarchy (Ancestors)

Hospital UnitsHealth FacilitiesHealth Care Facilities Workforce and Services

Study Officials

  • christian COMBE, MD

    University Hospital, Bordeaux

    STUDY DIRECTOR
  • Christian COMBE, MD

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2011

First Posted

August 1, 2011

Study Start

July 1, 2011

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

November 20, 2012

Record last verified: 2012-11

Locations